<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03149640</url>
  </required_header>
  <id_info>
    <org_study_id>PHRN15-SE / AMIKINHAL</org_study_id>
    <nct_id>NCT03149640</nct_id>
  </id_info>
  <brief_title>Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia</brief_title>
  <acronym>AMIKINHAL</acronym>
  <official_title>Double-blinded Multicenter Randomized Controlled Trial Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to prove that after the third day of invasive mechanical
      ventilation a three-day course of inhaled amikacin reduces the incidence of subsequent VAP.

      Parallel two group double blind randomized controlled clinical trial. Individual
      randomization, performed on day 4 of invasive mechanical ventilation, will be stratified on
      centre in order to account for variations in VAP prevention bundle implementation and use of
      systemic antibiotics the day of randomization. Patients will be treated three consecutive
      days with inhaled amikacin or placebo. Patients will be followed up daily in the intensive
      care unit for the occurrence of VAP according to international guidelines until day 28.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of a first VAP episode from randomization to day 28</measure>
    <time_frame>Patients will be followed from randomization to day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of a first VAP episode in the subgroups of patients with tracheobronchial colonization or tracheobronchitis</measure>
    <time_frame>At randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of VAP due to Gram negative amikacin sensitive bacteria</measure>
    <time_frame>Patients will be followed from randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pulmonary infection score evolution</measure>
    <time_frame>Patients will be followed from randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator associated events incidence</measure>
    <time_frame>Patients will be followed from randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of systemic antibiotics administered per day</measure>
    <time_frame>Patients will be followed from randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with at least one administration of a systemic antibiotic</measure>
    <time_frame>Patients will be followed from randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antibiotic resistant bacteria isolated on clinical and hygiene samples</measure>
    <time_frame>Patients will be followed from randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute kidney injury</measure>
    <time_frame>Patients will be followed from randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days spent on mechanical ventilation from randomization to day 90</measure>
    <time_frame>Patients will be followed from randomization to day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days from randomization to the first successful spontaneous breathing trial</measure>
    <time_frame>Days from randomization to day 90 max</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days spent in the intensive care unit and in the hospital</measure>
    <time_frame>Patients will be followed from randomization to discharge (day 90 max)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 90 mortality</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bacteria producing extended spectrum beta-lactamase or high level derepressed celphalosporinase, of vancomycin resistant Enterococcus Sp. on rectal samples</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative bacterial species composition of respiratory and digestive microbiota</measure>
    <time_frame>Patients will be followed from randomization to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum Concentration</measure>
    <time_frame>Between Hour 0-Hour 8, between Hour 8-Hour 16 and between Hour 16-Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum sputum Concentration</measure>
    <time_frame>Between Hour 0-Hour 8, between Hour 8-Hour 16 and between Hour 16-Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve</measure>
    <time_frame>Between Hour 0-Hour 8, between Hour 8-Hour 16 and between Hour 16-Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects on respiratory mechanics of nebulization of amikacin by evaluating the benefit balance / risk</measure>
    <time_frame>Measurements at 8 hours, 12 hours and 24 hours after the end of nebulization</time_frame>
    <description>benefit : Improvement of respiratory mechanics by pharmacological effect risk : Degradation of respiratory mechanics by bronchospastic secondary effect, drug deposition in the intubation probe</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Pneumonia, Ventilator-Associated</condition>
  <arm_group>
    <arm_group_label>Inhaled amikacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled amikacin</intervention_name>
    <description>Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.</description>
    <arm_group_label>Inhaled amikacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled placebo</intervention_name>
    <description>Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18 years the day of inclusion

          -  Mechanical ventilation through an endotracheal tube for more than three consecutive
             days (72h)

          -  Written informed consent of the patient or a proxy

          -  Patients covered by or having the rights to French social security

          -  Negative pregnancy test, at the time of inclusion, in women of childbearing potential

        Exclusion Criteria:

          -  Suspicion or confirmed VAP the day of inclusion

          -  Clinical indication for systemic aminoglycoside therapy the day of inclusion : as
             deemed necessary by the clinician in charge

          -  Stage 2 or 3 KDIGO* classification acute kidney injury the day of inclusion excepted
             in patients undergoing renal replacement therapy

          -  Chronic kidney failure : baseline glomerular filtration lower than 30 mL/min

          -  Patient scheduled for extubation within the next 24h

          -  Patient ventilated through an endotracheal tube for more than four consecutive days
             before inclusion (96h)

          -  Patient ventilated through a tracheostomy

          -  Patients allergic to aminoglycosides

          -  Myasthenia gravis

          -  Known pregnant women at the time of inclusion and lactating patients

          -  Known guardianship or trusteeship at the time of inclusion

          -  Patients previously included in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan EHRMANN, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan EHRMANN, MD-PhD</last_name>
    <phone>+33(0)2.47.47.98.51</phone>
    <email>stephanehrmann@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie LECLERC</last_name>
    <phone>+33(0)2.47.47.46.64</phone>
    <email>m.leclerc@chu-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de RÃ©animation Chirurgicale</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigismond LASOCKI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale - CH d'AngoulÃªme</name>
      <address>
        <city>AngoulÃªme</city>
        <zip>16959</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David SCHNELL, MD</last_name>
    </contact>
    <investigator>
      <last_name>David SCHNELL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation - CH Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jack RICHECOEUR, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale - HÃ´pital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien ROUX, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Damien ROUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre QUENOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre QUENOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale - CHD Les Oudairies</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85025</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Claude LACHERADE, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Claude LACHERADE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mickael LANDAIS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale - HÃ´pital La Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claude GUERIN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale - CH de Montauban</name>
      <address>
        <city>Montauban</city>
        <zip>82013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FrÃ©dÃ©ric BELLEC, MD</last_name>
    </contact>
    <investigator>
      <last_name>FrÃ©dÃ©ric BELLEC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoganaden MOOTIEN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale</name>
      <address>
        <city>OrlÃ©ans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry BOULAIN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale - HÃ´pital PitiÃ© SalpÃªtriÃ¨re</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qin LU-GU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale - CHU La MilÃ©trie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire DAHYOT-FIZELIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne VEINSTEIN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale - CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphaelle LARMET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Raphaelle LARMET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale - CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BenoÃ®t VEBER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale - HÃ´pital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaetan BEDUNEAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gaetan BEDUNEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation - NHC</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferhat MEZIANI, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Fehrat MEZIANI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation MÃ©dicale - HÃ´pital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Etienne HERBRECHT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Etienne HERBRECHT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de RÃ©animation mÃ©dicale, HÃ´pital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine FERRANDIERE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Martine FERRANDIERE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>inhaled amikacin</keyword>
  <keyword>placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

